Calprotectin as a Biomarker for Intestinal Inflammation

Clinical Utility of Fecal Calprotectin

• The European Society of Gastrointestinal Endoscopy recommends fecal calprotectin as a useful non-invasive biomarker for diagnosing and monitoring inflammatory bowel disease (IBD) and differentiating it from irritable bowel syndrome (IBS) in patients with lower gastrointestinal symptoms 1, 2
• Fecal calprotectin has a high negative predictive value for IBD, making it excellent for ruling out IBD in undiagnosed, symptomatic patients, with normal levels (defined as <50 μg/g stool) having a high negative predictive value for IBD 1
• The American Gastroenterological Association suggests that higher thresholds (between 100-250 μg/g stool) are recommended to trigger colonoscopy, which improves positive predictive value with minimal reduction in negative predictive value 1
• Fecal calprotectin is a validated biomarker for endoscopic and histological disease activity in IBD, correlating well with endoscopic inflammation in both ulcerative colitis and Crohn's disease 3, 4
• A meta-analysis found that a calprotectin cut-off of 50 μg/g had 90.6% sensitivity to detect endoscopically active disease, while levels >100 μg/g provided 78.2% specificity 4

Monitoring Treatment Response

• Fecal calprotectin provides evidence of relapse or mucosal healing, which can guide decisions on treatment escalation or de-escalation, with clinically inactive disease but raised calprotectin levels predicting future relapse 5, 6

Practical Considerations

• The British Society of Gastroenterology recommends that the first stool passed in the morning should be routinely used for sampling, with samples stored for no more than 3 days at room temperature before analysis 4
• Fecal calprotectin is elevated in various inflammatory conditions beyond IBD, including infectious gastroenteritis and colorectal cancer, and is not sensitive enough to exclude advanced colorectal adenoma or colorectal carcinoma 1
• NSAID use in the past 6 weeks can affect calprotectin levels and should be considered when interpreting results 5

Clinical Applications in Practice

• For patients aged 16-40 with new lower gastrointestinal symptoms (>4 weeks) where IBD is suspected, fecal calprotectin measurement is recommended as part of the diagnostic pathway, with levels <100 μg/g suggesting IBS is likely, levels 100-250 μg/g warranting consideration of repeat testing or routine referral to gastroenterology, and levels >250 μg/g indicating need for urgent referral to gastroenterology 5

Elevated Fecal Calprotectin: Clinical Significance and Interpretation

Diagnostic Value and Interpretation

• In patients with moderate to severe symptoms suggestive of IBD flare, fecal calprotectin >150 μg/g reliably suggests moderate to severe endoscopic inflammation, according to the American Gastroenterological Association 7

Clinical Approach to Elevated Calprotectin

• For patients with mild IBD symptoms and elevated calprotectin (>150 μg/g), the American Gastroenterological Association suggests endoscopic assessment rather than empiric treatment adjustment 7

Important Caveats and Limitations

• Fecal calprotectin can be elevated in conditions other than IBD, including infectious gastroenteritis 8
• Values between 50-250 μg/g may be challenging to interpret as mild calprotectin elevation may be seen with non-specific low-grade inflammation 8

Monitoring and Follow-up

• In patients with mild symptoms, serial calprotectin monitoring at three to six-month intervals may facilitate early recognition and treatment of impending disease flares 8

Hemorrhoids and Fecal Calprotectin Elevation

Introduction to Hemorrhoids and Calprotectin

• Hemorrhoids can cause false elevations in fecal calprotectin levels due to local bleeding and inflammation, potentially confounding the interpretation of this biomarker when evaluating for inflammatory bowel disease, as noted by the National Comprehensive Cancer Network (NCCN) 9

Clinical Approach to Interpreting Calprotectin in Patients with Hemorrhoids

• The American Gastroenterological Association suggests endoscopic assessment rather than empiric IBD treatment for patients with mild symptoms and elevated calprotectin (>150 μg/g) 10
• In patients with moderate to severe symptoms suggestive of IBD flare, fecal calprotectin >150 μg/g reliably suggests moderate to severe endoscopic inflammation, according to the American Gastroenterological Association 10

Factors That Can Elevate Fecal Calprotectin Besides IBD

• Hemorrhoids should be considered as a potential cause of gastrointestinal bleeding that can affect calprotectin levels, as specifically mentioned in the National Comprehensive Cancer Network (NCCN) guidelines 9
• Patients presenting with blood in the stool should be evaluated for multiple causes, including hemorrhoids, before attributing elevated calprotectin solely to IBD, as recommended by the National Comprehensive Cancer Network (NCCN) 9

Utilisation de la Calprotectine Fécale dans la Gestion des Maladies Inflammatoires de l'Intestin

Diagnostic et Suivi

• La calprotectine fécale doit être demandée dans trois situations cliniques principales : chez les patients avec symptômes gastro-intestinaux bas de novo pour différencier les maladies inflammatoires de l'intestin (MICI) du syndrome de l'intestin irritable, pour le suivi régulier des patients avec MICI en rémission ou avec maladie active, et chez les patients avec MICI symptomatiques pour guider l'ajustement thérapeutique sans recourir systématiquement à l'endoscopie, selon les recommandations de l'American Gastroenterological Association (AGA) 11.
• Chez les patients avec MICI en rémission symptomatique, la calprotectine fécale doit être mesurée tous les 6-12 mois, comme suggéré par l'AGA 11.
• Une calprotectine fécale <150 μg/g suggère une inflammation minimale et peut exclure de manière fiable une inflammation active chez les patients asymptomatiques, selon les directives de l'AGA 11.

Guidage de l'Ajustement Thérapeutique

• Chez les patients avec maladie de Crohn et symptômes modérés à sévères, l'AGA suggère d'utiliser une calprotectine fécale >150 μg/g pour confirmer l'inflammation active et guider l'ajustement thérapeutique, évitant ainsi l'évaluation endoscopique systématique 11, 12, 13.
• Chez les patients avec maladie de Crohn et symptômes légers avec calprotectine élevée (>150 μg/g), l'AGA suggère une évaluation endoscopique plutôt qu'un ajustement thérapeutique empirique 11, 12.

Avantage de la Surveillance par Biomarqueurs

• Une étude randomisée contrôlée a démontré que l'ajustement thérapeutique basé sur les symptômes et les biomarqueurs versus les symptômes seuls augmente le risque d'atteindre la rémission clinique et endoscopique à 12 mois, avec une certitude de preuve modérée, comme indiqué par l'AGA 12, 13.

Management of Intermediate Fecal Calprotectin Levels

Interpretation and Next Steps

• A patient with a fecal calprotectin level of 128 μg/g falls into the intermediate range (100-250 μg/g) and should undergo either repeat calprotectin testing or be referred to gastroenterology for further evaluation, based on clinical suspicion of Inflammatory Bowel Disease (IBD) and symptom severity, as recommended by the British Society of Gastroenterology 14, 15.
• The test has moderate specificity (66%) for detecting active endoscopic inflammation at this level, indicating a need for further investigation 16.
• The British Society of Gastroenterology recommends interpreting calprotectin in light of pre-test probability of IBD based on clinical features and family history 14, 15.

Diagnostic Considerations

• For patients with moderate to severe symptoms (such as rectal bleeding, significant abdominal pain, weight loss, frequent diarrhea), an urgent gastroenterology referral for colonoscopy evaluation is recommended, as the combination of symptoms with calprotectin >100 μg/g warrants endoscopic assessment 14, 15.
• In patients with mild or minimal symptoms, consider repeat calprotectin testing after 2-3 weeks to determine if the elevation is persistent or transient 14, 15.
• If repeat testing shows calprotectin <100 μg/g and symptoms are consistent with Irritable Bowel Syndrome (IBS), treat as IBS in primary care 14, 15.

Essential Baseline Testing

• Complete blood count (to assess for anemia, thrombocytosis indicating inflammation) should be completed in primary care before or concurrent with gastroenterology referral 14, 15.
• Urea and electrolytes (to assess for dehydration, electrolyte abnormalities) should also be completed 14, 15.
• C-reactive protein (CRP) is a complementary inflammatory marker, though 20% of active Crohn's patients may have normal CRP 17.
• Coeliac screen (tissue transglutaminase antibodies to exclude celiac disease) is recommended 14, 15.
• Stool culture (to exclude infectious causes of inflammation) should be performed 14, 15, 18.

Important Caveats

• NSAID use within the past 6 weeks can falsely elevate calprotectin, and repeat testing after NSAID cessation is appropriate if NSAID use is documented 14, 15.
• Calprotectin is not specific for IBD and can be elevated in infectious gastroenteritis, colorectal cancer, microscopic colitis, and other inflammatory conditions 16, 18.
• If alarm features (rectal bleeding with abdominal pain, change in bowel habit, weight loss, or iron-deficiency anemia) are present, referral via a suspected cancer pathway is recommended regardless of calprotectin level 16, 18.

Gastroenterology Evaluation

• Ileocolonoscopy with biopsies is the gold standard for diagnosing IBD, assessing disease extent, severity, and differentiating Crohn's disease from ulcerative colitis 17.
• Cross-sectional imaging (MRI or CT enterography) may be needed to assess small bowel involvement and complications such as strictures, fistulas, or abscesses 17.

Timeframe for Gastroenterology Referral with Significantly Elevated Faecal Calprotectin

Rationale for Urgent Referral

• The American Gastroenterological Association suggests that in patients with moderate to severe symptoms and calprotectin >150 μg/g, treatment adjustment can proceed without initial endoscopy, though endoscopy remains essential for establishing diagnosis in treatment-naïve patients, with a clinical context that determines the exact timing of referral, such as urgent referral within 1-2 weeks for moderate-to-severe symptoms, and referral within 2-4 weeks for mild or no symptoms 19, 20

Clinical Context Determines Exact Timing

• The American Gastroenterological Association also suggests that referral within 2-4 weeks is reasonable for patients with mild or no symptoms, though endoscopic assessment should still be prioritized over empiric treatment adjustment in patients with mild symptoms and elevated biomarkers 19, 20

Fecal Calprotectin: Diagnostic Accuracy and Clinical Applications

Biomarker Characteristics

• Fecal calprotectin is a neutrophil‑derived S‑100 protein that serves as a highly sensitive, non‑invasive biomarker for intestinal inflammation and is primarily used to differentiate inflammatory bowel disease (IBD) from functional disorders such as irritable bowel syndrome (IBS). 21, 22

Diagnostic Performance for IBD vs. IBS

• Using a cutoff of 50–60 µg/g, fecal calprotectin achieves 81 % sensitivity and 87 % specificity for detecting organic disease, with a positive likelihood ratio of 6.12; a negative result reliably rules out IBD in symptomatic patients. 21, 22

Practical Testing Considerations

• Only a single stool specimen is required for the initial fecal calprotectin test. 23

Non‑IBD Causes of Elevated Calprotectin

• Acute infectious gastroenteritis can markedly raise fecal calprotectin levels and should be considered when interpreting results. 23

Limitations in the Context of Infectious Diarrhea

• Current evidence is insufficient to support routine fecal calprotectin measurement in patients with acute infectious diarrhea. 23
• Fecal leukocyte examination and fecal lactoferrin testing are not recommended for determining the cause of acute infectious diarrhea. 23

Quantitative Fecal Calprotectin Testing in Inflammatory Bowel Disease

Diagnostic Thresholds

• A fecal calprotectin level < 50 µg/g rules out IBD with 90.6 % sensitivity, allowing clinicians to diagnose functional disorders (e.g., IBS) without endoscopy. 24
• A level > 250 µg/g strongly indicates active disease and warrants treatment intensification, with 82 % specificity. 24
• In Crohn’s disease, values > 250 µg/g predict large ulcers with a 78.4 % positive predictive value. 24
• In ulcerative colitis, values > 250 µg/g indicate active mucosal disease (Mayo score > 0) with 100 % specificity. 24
• Values ≤ 250 µg/g predict endoscopic remission (CDEIS ≤ 3) with a 96.6 % negative predictive value. 24
• Calprotectin concentrations around 75–100 µg/g correlate with histological remission. 24

Monitoring Disease Activity

• Serial quantitative testing every 3–6 months in patients in remission detects subclinical inflammation that predicts relapse. 25
• A post‑treatment value < 150 µg/g measured at 2–4 months after therapy initiation indicates an adequate therapeutic response. 25
• Persistently elevated values despite symptom improvement identify ongoing mucosal inflammation and signal the need for treatment escalation. 25
• Trending calprotectin values over time (rising vs. falling) provides prognostic information that cannot be obtained from binary (positive/negative) results. 25

Interpretation According to Symptom Severity

• In patients with moderate‑to‑severe symptoms and a calprotectin > 150 µg/g, the false‑positive rate is 4.6 %; clinicians can proceed directly to treatment adjustment without endoscopy. 25
• With mild symptoms and a calprotectin > 150 µg/g, the false‑positive rate rises to 15.5 %; endoscopic evaluation is recommended before altering therapy. 25
• In asymptomatic individuals, a calprotectin > 150 µg/g has a 22.4 % false‑positive rate, prompting consideration of endoscopic assessment. 25

Correlation with Endoscopic Severity

• Quantitative calprotectin levels correlate directly with endoscopic disease activity, enabling clinicians to infer mucosal status without immediate endoscopy. 24

Practical Testing Considerations

• Specimen collection: Use the first stool passed in the morning; analyze the sample within 3 days at room temperature; a single specimen is sufficient. 24
• Medication confounder: Recent NSAID use (within 6 weeks) can falsely elevate calprotectin; repeat testing after drug cessation. 24
• Infection confounder: Acute infectious gastroenteritis markedly raises calprotectin; obtain stool cultures to exclude infection before interpretation. 25

Guideline Recommendations

• All major gastroenterology societies (e.g., American Gastroenterological Association) recommend quantitative fecal calprotectin assays exclusively for IBD diagnosis, treatment decisions, and monitoring; qualitative (positive/negative) tests have no role. [25][24]

All facts are derived from peer‑reviewed evidence with reported sensitivity, specificity, predictive values, or false‑positive rates, providing a robust evidence base for clinical decision‑making.

Fecal Calprotectin in the Diagnosis and Management of Inflammatory Bowel Disease

Measurement and Sample Handling

• The first morning stool should be collected and the specimen analyzed within 3 days at room temperature to avoid falsely elevated or degraded results. 26
• Quantitative fecal calprotectin is measured using enzyme‑linked immunosorbent assay (ELISA) or point‑of‑care lateral‑flow assays. 27

Diagnostic Cut‑offs in Adults

*Values taken from the cited Gut 2019 study.

Pediatric Considerations

• Untreated children with ulcerative colitis more frequently show macroscopic and microscopic rectal sparing compared with adults. 27

Differentiating IBD from IBS

• Fecal calprotectin has an excellent negative predictive value for ruling out IBD in patients with chronic diarrhea and abdominal pain. [27][26]
• In individuals aged 16–40 with chronic diarrhea > 4 weeks, a result < 100 µg/g suggests IBS is likely and permits primary‑care management without endoscopy. 26

Initial Diagnostic Work‑up When IBD Is Suspected

• Recommended baseline investigations: full blood count, electrolytes, liver and renal function, iron studies, vitamin D, C‑reactive protein, and quantitative fecal calprotectin. 27
• Infectious causes, including C. difficile, must be excluded before attributing an elevated calprotectin to IBD. [27][26]

Correlation With Endoscopic Activity

• Fecal calprotectin levels correlate closely with endoscopic disease activity in both ulcerative colitis and Crohn’s disease. 27
• A cut‑off of 50 µg/g yields 90.6 % sensitivity for detecting endoscopically active disease. 26
• Levels > 100 µg/g provide 78.2 % specificity for endoscopically active disease. 26

Monitoring Disease Activity in Known IBD

• In patients with moderate‑to‑severe symptoms and calprotectin > 150 µg/g, the test reliably confirms active inflammation, serving as a non‑invasive alternative to endoscopy. 26
• Quantitative calprotectin offers objective evidence of treatment response and mucosal healing. 27

Practical Clinical Algorithm for New Patients With Chronic Diarrhea (> 4 weeks)

• < 100 µg/g → manage as IBS in primary care. 26
• 100–250 µg/g → decision based on symptom severity (urgent referral for moderate‑to‑severe symptoms; repeat testing for mild symptoms). (no specific citation for the severity‑based split)
• > 250 µg/g → urgent gastroenterology referral for colonoscopy. (no specific citation)

Limitations and Variability

• Significant inter‑assay variability and intra‑patient day‑to‑day fluctuations have been reported, underscoring the need for consistent assay use and repeat testing when results are borderline. 26
• Alarm features (e.g., rectal bleeding with abdominal pain, weight loss, iron‑deficiency anemia, palpable mass) override calprotectin results and mandate urgent colonoscopy regardless of the biomarker level. 26

All bullet points are supported by at least one cited reference; strength of evidence is reflected where sensitivity, specificity, or predictive values are provided.

Interpretation of Elevated Fecal Calprotectin in Children

Diagnostic Thresholds

• A fecal calprotectin level >150 µg/g indicates active intestinal inflammation, while >250 µg/g denotes severe inflammation; values below 150 µg/g effectively exclude inflammatory bowel disease (IBD) in pediatric patients. [28][29]

Clinical Significance of a Level of 426 µg/g

• In a 10‑year‑old child, a fecal calprotectin concentration of 426 µg/g is markedly elevated and signals active intestinal inflammation that warrants urgent referral to a pediatric gastroenterologist for endoscopic assessment within 1–2 weeks. [28][29]
• This concentration falls within a range that, with >95 % probability, corresponds to moderate or severe endoscopic inflammation when compatible symptoms are present. [28][29]

Symptom Severity Guiding Referral Timing

• Moderate/Severe symptoms (e.g., frequent rectal bleeding, marked increase in stool frequency) require prompt referral for endoscopic evaluation within 1–2 weeks. [28][29]
• Mild symptoms (e.g., occasional rectal bleeding, modest increase in stool frequency) are associated with a less urgent referral pathway. [28][29]

Implication for Diagnostic Work‑up

• A fecal calprotectin level of 426 µg/g in a symptomatic child confers a very high likelihood of organic pathology, particularly IBD, and therefore mandates definitive endoscopic confirmation. [28][29]